CytomX Therapeutics, Inc.
Business
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated, masked biologics through its proprietary PROBODY platform technology. The company's lead candidates include Varseta-M, a masked antibody-drug conjugate targeting EpCAM in colorectal cancer, and CX-801, a masked interferon alpha-2b cytokine in Phase 1 development for melanoma. CytomX applies its platform across multiple modalities including antibody-drug conjugates, T-cell engagers, cytokines, and mRNA-based therapeutics, partnering with companies including Amgen, Bristol Myers Squibb, Astellas, Regeneron, and Moderna to extend platform reach.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 76 | 138 | 101 | 53 | 37 | |
| Research and development | 69 | 83 | 78 | 112 | 114 | |
| General and administrative | 30 | 30 | 30 | 43 | 39 | |
| Total operating expenses | 99 | 113 | 108 | 154 | 153 | |
| Income (loss) from operations | −22 | 25 | −6 | −101 | −116 | |
| Interest income | 5 | 7 | 10 | 2 | 255,000 | |
| Other income (expense), net | 28,000 | −38,000 | −30,000 | 340,000 | −83,000 | |
| Income (loss) before income taxes | −17 | 32 | 3 | −99 | −116 | |
| Provision for income taxes | 238,000 | 224,000 | 4 | 0 | 0 | |
| Net income (loss) | −17 | 32 | — | — | — | |
| Net income (loss) | −17 | 32 | −569,000 | −99 | −116 | |
| Deemed dividend on warrants | −3 | 0 | — | — | — | |
| Net income (loss) attributable to common stockholders | −20 | 32 | — | — | — | |
| Unrealized gain (loss) on available-for-sale investments, net of tax | 84,000 | −68,000 | 85,000 | 252,000 | −195,000 | |
| Total comprehensive income (loss) | −17 | 32 | −484,000 | −99 | −116 | |
| Net income (loss) per share, Basic | −0.15 | 0.38 | −0.01 | −1.51 | −1.81 | |
| Net income (loss) per share, Diluted | −0.15 | 0.38 | −0.01 | −1.51 | −1.81 | |
| Shares used to compute net income (loss) per share, Basic | 138 | 84 | 74 | 66 | 64 | |
| Shares used to compute net income (loss) per share, Diluted | 138 | 85 | 74 | 66 | 64 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 38 | 17 | 194 | — | |
| Short-term investments | 124 | 63 | 157 | 0 | — | |
| Accounts receivable | 2 | 3 | 3 | 36 | — | |
| Prepaid expenses and other current assets | 5 | 4 | 5 | 7 | — | |
| Total current assets | 144 | 107 | 183 | 237 | — | |
| Property and equipment, net | 1 | 2 | 4 | 5 | — | |
| Intangible assets, net | 438,000 | 583,000 | 729,000 | 875,000 | — | |
| Goodwill | 949,000 | 949,000 | 949,000 | 949,000 | — | |
| Restricted cash | 2 | 1 | 917,000 | 917,000 | — | |
| Operating lease right-of-use asset | 3 | 8 | 12 | 16 | — | |
| Other assets | 31,000 | 66,000 | 83,000 | 27,000 | — | |
| Total assets | 152 | 121 | 202 | 261 | — | |
| Accounts payable | 1 | 1 | 1 | 3 | — | |
| Accrued liabilities | 14 | 12 | 18 | 24 | — | |
| Operating lease liabilities - short term | 4 | 5 | 5 | 4 | — | |
| Deferred revenue, current portion | 27 | 67 | 132 | 121 | 87 | |
| Total current liabilities | 47 | 86 | 156 | 153 | 124 | |
| Deferred revenue, net of current portion | 2 | 27 | 80 | 180 | 168 | |
| Operating lease liabilities - long term | 0 | 4 | 9 | 14 | — | |
| Other long-term liabilities | 4 | 4 | 4 | 0 | — | |
| Total liabilities | 53 | 121 | 249 | 347 | 307 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding | 0 | 0 | — | — | — | |
| Common stock, $0.00001 par value; 300,000,000 and 150,000,000 shares authorized, and 170,186,365 and 80,099,889 shares issued and outstanding at December 31, 2025 and 2024, respectively | 2,000 | 1,000 | 1,000 | 1,000 | — | |
| Additional paid-in capital | 811 | 691 | 676 | 637 | — | |
| Accumulated other comprehensive income | 111,000 | 27,000 | 95,000 | 10,000 | — | |
| Accumulated deficit | −712 | −692 | −723 | −723 | −714 | |
| Total stockholders' equity (deficit) | 99 | −456,000 | −47 | −86 | −81 | |
| Total liabilities and stockholders' equity (deficit) | 152 | 121 | 202 | 261 | 226 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization of intangible assets | 146,000 | 146,000 | 146,000 | 146,000 | 146,000 | |
| Depreciation and amortization | 1 | 2 | 2 | 2 | 3 | |
| Impairment loss on machinery and equipment | 402,000 | 106,000 | 0 | 254,000 | — | |
| Accretion of discounts on short-term investments | −2 | −5 | −7 | −52,000 | 272,000 | |
| Stock-based compensation expense | 6 | 8 | 9 | 13 | 13 | |
| Non-cash lease expense | 4 | 4 | 4 | 3 | 3 | |
| Accounts receivable | 1 | 329,000 | 33 | −35 | 8,000 | |
| Prepaid expenses and other assets | −1 | 1 | 2 | −3 | 3 | |
| Accounts payable | 221,000 | −297,000 | −1 | 68,000 | −139,000 | |
| Accrued liabilities and other long-term liabilities | −3 | −10 | −7 | −10 | — | |
| Deferred revenue | −66 | −118 | −89 | 17 | −34 | |
| Net cash used in operating activities | −76 | −86 | −56 | −111 | −119 | |
| Purchases of property and equipment | −220,000 | −310,000 | −840,000 | −2 | −2 | |
| Purchases of short term investments | −193 | −155 | −425 | 0 | −100 | |
| Maturities of short term investments | 133 | 256 | 275 | 100 | 124 | |
| Net cash provided by (used in) investing activities | −60 | 100 | −151 | 98 | 22 | |
| Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost | 0 | 0 | 30 | 0 | — | |
| Proceeds from issuance of common stock, net of issuance cost | 110 | 7 | — | 0 | 108 | |
| Proceeds from employee stock purchase plan and exercise of stock options | 811,000 | 613,000 | 561,000 | 648,000 | 3 | |
| Net cash provided by financing activities | 110 | 8 | 30 | 648,000 | 110 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −25 | 21 | −176 | −12 | 14 | |
| Purchases of property and equipment in accounts payable and accrued liabilities | 0 | 8,000 | 75,000 | 6,000 | 83,000 | |
| Deemed dividend on warrants | 3 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CytomX Therapeutics, Inc.'s CIK number?
CytomX Therapeutics, Inc.'s SEC CIK number is 0001501989 (1501989). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CytomX Therapeutics, Inc.'s SEC filings?
All of CytomX Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CytomX Therapeutics, Inc. last report earnings?
CytomX Therapeutics, Inc. (CTMX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211920). This is CytomX Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is CytomX Therapeutics, Inc.'s most recent earnings 8-K?
CytomX Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211920. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CytomX Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →